Bristol-Myers Squibb Company
BMYBristol-Myers Squibb Company is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are Apixaban (Eliquis) for people with atrial fibrillation (28% of 2024 revenues); nivolumab (Opdivo), used to treat certain types of cancer (19% of 2024 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (12% of 2024 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2024 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (8% of 2024 revenues); ipilimumab (Yervoy), to treat cancer (5% of 2024 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (4% of 2024 revenues). In 2024, 71% of the company's revenues came from the United States.
Drugs in Pipeline
75
Phase 3 Programs
38
Upcoming Catalysts
9
Next Catalyst
Nov 1, 2026
31wMarket Overview
Stock performance and key metrics
10 upcoming, 1 past
NKTR-214
Melanoma
BMS-986165
Ulcerative Colitis
KarXT
Bipolar-I Disorder With Mania or Mania With Mixed Features
Ozanimod
Colitis, Ulcerative
Intravenous (IV) abatacept
Rheumatoid Arthritis
Abatacept
Nephrotic Syndrome
Belatacept
Kidney Transplantation
Paclitaxel
Lung Cancer
Carboplatin
Non-Small Cell Lung Cancer
mavacamten
Hypertrophic Cardiomyopathy
BMS-986504
Pancreatic Ductal Adenocarcinoma
Irbesartan
Congestive Heart Failure
Deucravacitinib
Plaque Psoriasis
Pumitamig
Untreated, Unresectable, or Metastatic Colorectal Cancer
stavudine extended-release, lamivudine, efavirenz
HIV Infections
paclitaxel (PTX)
Breast Cancer
Indinavir sulfate
HIV Infections
Cyclophosphamide
Relapsed or Refractory Multiple Myeloma (RRMM)
Repotrectinib
Carcinoma, Non-Small-Cell Lung
Ipilimumab
Melanoma
BMS-790052 (Daclatasvir)
Hepatitis C
Peginterferon Lambda-1a
Hepatitis C Virus
cisplatin
Head and Neck Cancer
Dacarbazine
Melanoma
Cetuximab/Erbitux
Head and Neck Cancer
Imatinib
Chronic Phase Chronic Myeloid Leukemia
Entecavir (ETV)
Hepatitis B
Tanespimycin
Multiple Myeloma
Apremilast
Psoriasis
Megestrol acetate
Anorexia
Iza-bren
Non-Small Cell Lung Cancer
Relatlimab
Lymphoma, Non-Hodgkin
Muraglitazar
Diabetes Mellitus
Topotecan
Lung Cancer
Lenalidomide
Lymphoma
Dasatinib
Chronic Phase Chronic Myeloid Leukemia
Daclatasvir
Hepatitis C
Nivolumab
Brain Neoplasms
BMS-986179
Malignant Solid Tumor
Rituximab
Lymphoma
CC-97540
Lupus Erythematosus, Systemic
BMS-986177
Acute Ischemic Stroke
BMS-790052
Hepatitis C Infection
BMS-986178
Advanced Cancer
MDX-060
Hodgkin's Disease
BMS-986213
Gastric Cancer
Elotuzumab (BMS-901608; HuLuc63)
Smoldering Multiple Myeloma
BMS-770767
Dyslipidemia
Elotuzumab
Multiple Myeloma
Daratumumab
Various Advanced Cancer
CTLA4Ig / Abatacept
Psoriasis Vulgaris
Tyrosinase/gp100/MART-1 Peptides
Intraocular Melanoma
Trametinib
Colorectal Cancer
BMS-931699
Lupus
Dexamethasone
Multiple Myeloma
BMS-741672
Neuropathic Pain
BMS-690514
Breast Cancer
Ticagrelor
Coronary Artery Disease
SAR302503
Hematopoietic Neoplasm
docetaxel
Prostate Cancer
BMS-986207
Non-Small Cell Lung Cancer
BMS-986166
Dermatitis, Atopic
BMS-823778
Diabetes Mellitus, Type 2
Pexacerfont
Major Depressive Disorder
Pemetrexed
Non-Small Cell Lung Cancer
BMS-986016
Hematologic Neoplasms
Entecavir
Chronic Hepatitis B
Platinum Doublet Chemotherapy
Non-Small-Cell Lung Cancer
BMS-986408
Advanced Solid Tumors
Anti-IP-10 Antibody
Colitis, Ulcerative
Arlocabtagene Autoleucel
Multiple Myeloma
Apixaban
Deep-Vein Thrombosis
Luspatercept
Anemia
valacyclovir
Herpes Zoster
BMS-817399
Rheumatoid Arthritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NKTR-214 | Phase 3 | Melanoma | - | - |
BMS-986165 | Phase 3 | Ulcerative Colitis | - | - |
KarXT | Phase 3 | Bipolar-I Disorder With Mania or Mania With Mixed Features | - | - |
Ozanimod | Phase 3 | Colitis, Ulcerative | - | - |
Intravenous (IV) abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Abatacept | Phase 3 | Nephrotic Syndrome | - | - |
Belatacept | Phase 3 | Kidney Transplantation | - | - |
Paclitaxel | Phase 3 | Lung Cancer | - | - |
Carboplatin | Phase 3 | Non-Small Cell Lung Cancer | - | - |
mavacamten | Phase 3 | Hypertrophic Cardiomyopathy | - | - |
BMS-986504 | Phase 3 | Pancreatic Ductal Adenocarcinoma | - | - |
Irbesartan | Phase 3 | Congestive Heart Failure | - | - |
Deucravacitinib | Phase 3 | Plaque Psoriasis | - | - |
Pumitamig | Phase 3 | Untreated, Unresectable, or Metastatic Colorectal Cancer | - | - |
stavudine extended-release, lamivudine, efavirenz | Phase 3 | HIV Infections | - | - |
paclitaxel (PTX) | Phase 3 | Breast Cancer | - | - |
Indinavir sulfate | Phase 3 | HIV Infections | - | - |
Cyclophosphamide | Phase 3 | Relapsed or Refractory Multiple Myeloma (RRMM) | - | - |
Repotrectinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Ipilimumab | Phase 3 | Melanoma | - | - |
BMS-790052 (Daclatasvir) | Phase 3 | Hepatitis C | - | - |
Peginterferon Lambda-1a | Phase 3 | Hepatitis C Virus | - | - |
cisplatin | Phase 3 | Head and Neck Cancer | - | - |
Dacarbazine | Phase 3 | Melanoma | - | - |
Cetuximab/Erbitux | Phase 3 | Head and Neck Cancer | - | - |
Imatinib | Phase 3 | Chronic Phase Chronic Myeloid Leukemia | - | - |
Entecavir (ETV) | Phase 3 | Hepatitis B | - | - |
Tanespimycin | Phase 3 | Multiple Myeloma | - | - |
Apremilast | Phase 3 | Psoriasis | - | - |
Megestrol acetate | Phase 3 | Anorexia | - | - |
Iza-bren | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Relatlimab | Phase 3 | Lymphoma, Non-Hodgkin | - | - |
Muraglitazar | Phase 3 | Diabetes Mellitus | - | - |
Topotecan | Phase 3 | Lung Cancer | - | - |
Lenalidomide | Phase 3 | Lymphoma | - | - |
Dasatinib | Phase 3 | Chronic Phase Chronic Myeloid Leukemia | - | - |
Daclatasvir | Phase 3 | Hepatitis C | - | - |
Nivolumab | Phase 3 | Brain Neoplasms | - | - |
BMS-986179 | Phase 2 | Malignant Solid Tumor | - | - |
Rituximab | Phase 2 | Lymphoma | - | - |
CC-97540 | Phase 2 | Lupus Erythematosus, Systemic | - | - |
BMS-986177 | Phase 2 | Acute Ischemic Stroke | - | - |
BMS-790052 | Phase 2 | Hepatitis C Infection | - | - |
BMS-986178 | Phase 2 | Advanced Cancer | - | - |
MDX-060 | Phase 2 | Hodgkin's Disease | - | - |
BMS-986213 | Phase 2 | Gastric Cancer | - | - |
Elotuzumab (BMS-901608; HuLuc63) | Phase 2 | Smoldering Multiple Myeloma | - | - |
BMS-770767 | Phase 2 | Dyslipidemia | - | - |
Elotuzumab | Phase 2 | Multiple Myeloma | - | - |
Daratumumab | Phase 2 | Various Advanced Cancer | - | - |
CTLA4Ig / Abatacept | Phase 2 | Psoriasis Vulgaris | - | - |
Tyrosinase/gp100/MART-1 Peptides | Phase 2 | Intraocular Melanoma | - | - |
Trametinib | Phase 2 | Colorectal Cancer | - | - |
BMS-931699 | Phase 2 | Lupus | - | - |
Dexamethasone | Phase 2 | Multiple Myeloma | - | - |
BMS-741672 | Phase 2 | Neuropathic Pain | - | - |
BMS-690514 | Phase 2 | Breast Cancer | - | - |
Ticagrelor | Phase 2 | Coronary Artery Disease | - | - |
SAR302503 | Phase 2 | Hematopoietic Neoplasm | - | - |
docetaxel | Phase 2 | Prostate Cancer | - | - |
BMS-986207 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BMS-986166 | Phase 2 | Dermatitis, Atopic | - | - |
BMS-823778 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Pexacerfont | Phase 2 | Major Depressive Disorder | - | - |
Pemetrexed | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BMS-986016 | Phase 2 | Hematologic Neoplasms | - | - |
Entecavir | Phase 2 | Chronic Hepatitis B | - | - |
Platinum Doublet Chemotherapy | Phase 2 | Non-Small-Cell Lung Cancer | - | - |
BMS-986408 | Phase 2 | Advanced Solid Tumors | - | - |
Anti-IP-10 Antibody | Phase 2 | Colitis, Ulcerative | - | - |
Arlocabtagene Autoleucel | Phase 2 | Multiple Myeloma | - | - |
Apixaban | Phase 2 | Deep-Vein Thrombosis | - | - |
Luspatercept | Phase 2 | Anemia | - | - |
valacyclovir | Phase 2 | Herpes Zoster | - | - |
BMS-817399 | Phase 2 | Rheumatoid Arthritis | - | - |
Lymphoma
1 drug in this indication
Lupus Erythematosus, Systemic
1 drug in this indication
Multiple Myeloma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)